Biora Therapeutics, Inc. (BIOR)
NASDAQ: BIOR · IEX Real-Time Price · USD
0.642
+0.021 (3.40%)
At close: Apr 17, 2024, 4:00 PM
0.684
+0.042 (6.48%)
After-hours: Apr 17, 2024, 7:54 PM EDT
Company Description
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics.
The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases.
The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline.
Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
Biora Therapeutics, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jun 19, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Aditya P. Mohanty M.B.A. |
Contact Details
Address: 4330 La Jolla Village Drive, Suite 200 San Diego, California 92122 United States | |
| Phone | 855-293-2639 |
| Website | bioratherapeutics.com |
Stock Details
| Ticker Symbol | BIOR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001580063 |
| CUSIP Number | 74319F107 |
| ISIN Number | US74319F3055 |
| Employer ID | 27-3950390 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Aditya P. Mohanty M.B.A. | Chief Executive Officer and Director |
| Eric d'Esparbes | Chief Financial Officer |
| Clarke Neumann J.D. | Senior Vice President, General Counsel and Secretary |
| Eric Fox | Vice President of Finance and Accounting & Treasurer |
| Troy Seelye | Chief Information Officer |
| George Gianakopoulos | Senior Vice President of Sales |
| Robyn Hatton | Head of Human Resources |
| Kevin Howe Ph.D. | Senior Vice President of Strategic Operations |
| Dr. Sharat Singh Ph.D. | Head of Research |
| Dr. Paul Shabram M.B.A. | Head of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 8, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 2, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 2, 2024 | 8-K | Current Report |
| Apr 2, 2024 | 424B5 | Filing |
| Apr 2, 2024 | 424B5 | Filing |
| Apr 2, 2024 | 424B5 | Filing |
| Apr 2, 2024 | 424B5 | Filing |
| Apr 2, 2024 | 424B5 | Filing |
| Apr 2, 2024 | 424B5 | Filing |